Loading...
XNASSAVA
Market cap132mUSD
Jan 17, Last price  
2.75USD
1D
2.23%
1Q
-90.52%
Jan 2017
-31.10%
Name

Cassava Sciences Inc

Chart & Performance

D1W1MN
XNAS:SAVA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.46%
Rev. gr., 5y
%
Revenues
0k
P
05,080,00053,918,00065,984,00063,725,00020,563,00016,809,00011,484,00010,890,00041,119,00000000000-1,8000
Net income
-97m
L+34.14%
-37,776,000-30,670,0006,188,00020,305,00015,347,000-3,467,000-12,023,000-2,613,000-3,446,00031,544,000-12,386,000-14,145,000-14,850,000-11,911,000-6,557,000-4,245,000-5,854,000-31,802,000-72,472,000-97,217,000
CFO
-82m
L+5.82%
-32,569,000113,232,000-11,827,0002,231,00011,163,000-14,691,000-143,000-260,000-7,171,000-6,947,000-9,549,000-9,053,000-12,234,000-8,237,000-4,770,000-2,514,000-5,382,000-30,196,000-77,514,000-82,025,000
Dividend
Dec 13, 20120.75 USD/sh
Earnings
Feb 26, 2025

Profile

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
URL
https://www.cassavasciences.com/
IPO date
Jul 14, 2000
Employees
26
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
(2)
 
Cost of revenue
195,380
81,321
Unusual Expense (Income)
NOPBT
(195,380)
(81,323)
NOPBT Margin
4,517,933.33%
Operating Taxes
(3,774)
Tax Rate
NOPAT
(195,380)
(77,549)
Net income
(97,217)
34.14%
(72,472)
127.89%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,560
47,329
BB yield
-0.27%
-3.99%
Debt
Debt current
104
Long-term debt
174
Deferred revenue
Other long-term liabilities
223
Net debt
(121,136)
(200,737)
Cash flow
Cash from operating activities
(82,025)
(77,514)
CAPEX
(414)
(2,712)
Cash from investing activities
(414)
(2,712)
Cash from financing activities
2,560
47,804
FCF
(190,996)
(82,961)
Balance
Cash
121,136
201,015
Long term investments
Excess cash
121,136
201,015
Stockholders' equity
(380,727)
227,539
Invested Capital
518,195
26,886
ROIC
ROCE
EV
Common stock shares outstanding
41,932
40,202
Price
22.51
-23.80%
29.54
-32.40%
Market cap
943,889
-20.52%
1,187,567
-31.04%
EV
822,753
986,830
EBITDA
(193,850)
(80,022)
EV/EBITDA
Interest
3,774
Interest/NOPBT